(RTTNews) - Amphastar Pharmaceuticals, Inc. (AMPH) said the FDA has approved its Abbreviated New Drug Application for Glucagon for Injection Emergency Kit, 1 mg. Glucagon is indicated for the treatment of severe hypoglycemia and is also used as a diagnostic aid. The company plans to launch Glucagon for Injection Emergency Kit, which it previously referred to as AMP-001, within two months.
Amphastar's CEO, Jack Zhang, stated: "This approval is yet another milestone for the Company and marks the first-ever FDA approval of a generic version of rDNA Glucagon."
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
